Syntara Ltd (ASX: SNT) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Syntara Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $82.39 million
P/E Ratio 4.64
Dividend Yield 0.00%
Shares Outstanding 1.58 billion
Earnings per share -0.020
Dividend per share N/A
Year To Date Return 200.00%
Earnings Yield 21.54%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Syntara Ltd (ASX: SNT)
    Latest News

    medical asx share price represented by doctor giving thumbs up
    Share Market News

    Why the Pharmaxis (ASX:PXS) share price jumped 6% today

    The Pharmaxis Ltd (ASX: PXS) share price is up 6% during early afternoon trade. We look at the announcement driving…

    Read more »

    Share Market News

    Why the Pharmaxis (ASX:PXS) share price has rocketed up 48% today

    The Pharmaxis share price has shot up by 47.73% this morning after positive news about the product pipeline and short…

    Read more »

    Healthcare Shares

    ASX stock of the day: Pharmaxis share price surges 8% as milestone payment brought forward

    The Pharmaxis share price has surged 7% today after the company announced a US$7 million payment milestone had been brought…

    Read more »

    a woman
    Share Market News

    Is the Starpharma share price a buy?

    The Starpharma Holdings Limited (ASX: SPL) share price has gained 50% since the end of December 2018. Is it a…

    Read more »

    a woman
    ⏸️ Investing

    Warning: Every investor should read this before buying speculative biotech companies

    You could lose your shirt investing in companies like Innate Immunotherapeutics Ltd (ASX:IIL).

    Read more »

    a woman
    ⏸️ Investing

    This high-risk sector is one ALL new investors should avoid

    Australia's fledging biotech sector, filled with the likes of Cynata Therapeutics Ltd (ASX:CYP) and Pharmaxis Ltd (ASX:PXS) is not for…

    Read more »

    a woman
    ⏸️ Investing

    Revealed: This under-the-radar biotech has blockbuster potential

    Pharmaxis Ltd. (ASX:PXS) completes recruitment for Phase III cystic fibrosis trial.

    Read more »

    a woman
    ⏸️ Investing

    Here's why Prima Biomed Limited skyrocketed 59% today

    Prima Biomed Limited (ASX:PRR) isn't the only biotech exploding recently, with Pharmaxis Ltd. (ASX:PXS) and Sirtex Medical Limited (ASX:SRX) on…

    Read more »

    a woman
    ⏸️ Investing

    Here's why Pharmaxis Ltd. skyrocketed 60% today

    Pharmaxis Ltd. (ASX:PXS) shares gained more than 60% today, compared to a 1.1% decline for the ALL ORDINARIES (Index:^AXAO) (ASX:XAO).

    Read more »

    a woman
    ⏸️ Investing

    Here's why Pharmaxis Ltd. shares are soaring today

    Pharmaxis Ltd (ASX:PXS) is just one of Australia's biotech stocks bouncing today, with its shares up nearly 65%!

    Read more »

    a woman
    ⏸️ Investing

    6 stocks smashed on the ASX today

    The All Ordinaries closes flat, despite a strong start to the day

    Read more »

    a woman
    ⏸️ Investing

    4 stocks soaring on the ASX today

    S&P/ALL Ordinaries closes flat, but these four jumped more than 11%

    Read more »

    SNT ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Syntara Ltd

    Pharmaxis Ltd. is a pharmaceutical research company, which engages in the development and commercialization of healthcare products for fibrotic and inflammatory diseases. Its respiratory products include bronchitol and aridol. The company was founded by Brett Charlton and William B. Cowden on May 29, 1998 and is headquartered in Sydney, Australia.

    SNT Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 Dec 2024 $0.06 $0.00 0.00% 2,903,765 $0.06 $0.06 $0.06
    19 Dec 2024 $0.06 $0.00 0.00% 9,864,983 $0.06 $0.06 $0.06
    18 Dec 2024 $0.06 $-0.01 -14.49% 9,617,055 $0.07 $0.07 $0.06
    17 Dec 2024 $0.07 $0.00 0.00% 9,665,895 $0.07 $0.07 $0.07
    16 Dec 2024 $0.07 $0.01 15.15% 18,603,848 $0.07 $0.08 $0.07
    13 Dec 2024 $0.07 $0.00 0.00% 10,978,746 $0.07 $0.07 $0.06
    12 Dec 2024 $0.06 $0.00 0.00% 30,389,394 $0.06 $0.07 $0.06
    09 Dec 2024 $0.07 $0.00 0.00% 8,871,179 $0.07 $0.07 $0.07
    06 Dec 2024 $0.07 $0.01 15.63% 10,738,075 $0.07 $0.07 $0.07
    05 Dec 2024 $0.06 $0.00 0.00% 10,049,345 $0.07 $0.07 $0.06
    04 Dec 2024 $0.07 $0.00 0.00% 9,043,149 $0.07 $0.07 $0.07
    03 Dec 2024 $0.07 $0.01 16.67% 11,225,253 $0.06 $0.07 $0.06
    02 Dec 2024 $0.06 $0.00 0.00% 11,933,515 $0.06 $0.06 $0.06
    29 Nov 2024 $0.06 $0.01 20.00% 13,148,688 $0.05 $0.06 $0.05
    28 Nov 2024 $0.05 $0.00 0.00% 5,761,519 $0.05 $0.05 $0.05
    27 Nov 2024 $0.05 $0.01 23.81% 7,315,361 $0.04 $0.05 $0.04
    26 Nov 2024 $0.04 $0.00 0.00% 4,396,285 $0.05 $0.05 $0.04
    25 Nov 2024 $0.04 $0.00 0.00% 3,268,888 $0.05 $0.05 $0.04
    22 Nov 2024 $0.05 $0.00 0.00% 3,513,659 $0.05 $0.05 $0.04

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    29 Nov 2024 Gary Phillips Issued 2,771,000 $155,176
    Issue of options.
    23 Sep 2024 Waradana De Silva Issued 53,571,429 $1,500,000
    Placement. As per announcement on 24-09-2024
    13 Feb 2024 Waradana De Silva Issued 3,000,000 $66,000
    Issue of options.
    13 Feb 2024 Simon Green Issued 3,000,000 $66,000
    Issue of options.
    06 Feb 2024 Simon Green Issued 909,091 $20,000
    Placement.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Gary Phillips Chief Executive OfficerManaging Director Mar 2013
    Mr Phillips was the Chief Operating Officer since June 2008, having previously served as Commercial Director from his joining of the Company in December 2003. Mr Phillips has more than 30 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia. From 1994 to 1998, he was Chief Executive Officer at Ciba Geigy in Hungary (Merged to form Novartis in 1996) where he led the launch of a portfolio of new products.
    Dr Simon Green Non-Executive Director Dec 2022
    Dr Green has 30 years of experience in the biotechnology industry focussed on the discovery, development and commercialisation of life saving medicines. He worked in the USA at leading biotechnology companies Genentech Inc and Chiron Corporation prior to joining CSL in 1998. Dr Green was actively involved in CSLs global expansion over a 17 year period and held roles as Senior Vice President, Global Plasma R&D and General Manager of CSLs manufacturing plants in Germany and Australia
    Dr Kathleen Mary Metters Non-Executive DirectorNon-Executive Chairman Jun 2017
    Dr Metters has over 25 years of experience in the discovery and development of novel therapies for treatment of serious diseases. She is currently working as an independent biopharma consultant, as senior advisor for New York-based Bridge Medicines, as a Non-Executive Director for Aslan Pharmaceuticals Ltd. and an independent board member for HemoShear Therapeutics. From 2011-2014 Dr Metters was President and Chief Executive officer for Lycera Corp., a biopharmaceutical company pioneering innovative approaches to novel oral medicines for treatment of autoimmune diseases and cancer.
    Mr Waradana Malitha Hashan De Silva Non-Executive Director Jan 2023
    Mr De Silva is an experienced life sciences investment professional. He worked as associate healthcare analyst at Macquarie Group and lead healthcare analyst at CLSA Australia before joining Karst Peak Capital in February 2021 as head of healthcare research. Prior to moving into life science investment Mr De Silva worked at Eli Lilly in various roles focused on the commercialisation of new and existing pharmaceuticals.
    Mr David Morris McGarvey Company Secretary Chief Financial officer
    -
    Kristen Morgan Alliance Management Head of Medical and Regulatory Affairs
    -
    Jana Baskar Chief Medical Officer
    -
    David Morris McGarvey Company Secretary Chief Financial officer
    -
    Wolfgang Jarolimek Head of Drug Discovery
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Citicorp Nominees Pty Limited 147,191,348 20.38%
    HSBC Custody Nominees (Australia) Limited A/C 2 108,361,494 15.01%
    Hsbc Custody Nominees (Australia) Limited 73,020,165 10.11%
    D and A Income Limited 38,690,477 5.36%
    Lawn Views Pty Ltd <Angela Williams Family A/C> 10,350,966 1.43%
    Dr Toby David Cohen 6,749,457 0.93%
    Bnp Paribas Noms Pty Ltd <Drp> 6,487,405 0.90%
    Healthcare Management Consulting (Australia) Pty Ltd 5,262,950 0.73%
    Mr David Curzon Smith and Mrs Diane Maurine Smith <Badham Family A/C> 4,255,715 0.59%
    Ms Bei Xu and Mr Dongning Wu 3,600,891 0.50%
    Indcorp Consulting Group Pty Limited <Superannuation Fund A/C> 3,000,001 0.42%
    Mr Xing Jiang Xue 2,729,886 0.38%
    Finter Nominees Pty Ltd <TJF Family A/C> 2,700,000 0.37%
    Pakasoluto Pty Limited <Barkl Family Super Fund A/C> 2,622,007 0.36%
    Mr Peter John Carr 2,510,000 0.35%
    Bnp Paribas Nominees Pty Ltd Acf Clearstream 2,503,208 0.35%
    Bunyula Super Pty Ltd <Bunyula Super Fund A/C> 2,477,076 0.34%
    Mr Joseph Wallace Carson 2,476,192 0.34%
    Mr Gregory Bruce Cole and Mrs Julia Theresa Cole <Greg & Julie Super Fund A/C> 2,430,000 0.34%
    Mrs Sharon Lewis 2,265,715 0.31%

    Profile

    since

    Note